Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives... Show more
Accuray's first quarter fiscal 2027 report lands at a pivotal moment in the radiation therapy company's transformation. After a fiscal 2026 marked by restructuring, cost reductions, and a financing transaction with TCW, investors are watching whether the company can convert its operational progress into renewed product demand. The quarter highlights a widening gap between a resilient, high-margin service business and a product segment pressured by geopolitical tensions and softness in China. With order volumes and backlog under scrutiny, this report offers a key read on whether Accuray's cost discipline and improved service economics can offset persistent demand headwinds and stabilize its financial footing.
Accuray reported total net revenue of $86.5 million for the first quarter of fiscal 2027, down $7.4 million, or 8%, from the prior-year period, and down 7% on a constant currency basis. This came in below the consensus estimate of roughly $95.8 million.
Service revenue grew 4% year over year to $59.2 million, up 5% on a constant currency basis, driven by pricing actions and growth in the global installed base. Product revenue declined to $27.3 million from $37.2 million, reflecting geopolitical factors and market issues in China.
Net income was $10.1 million, or $0.07 per diluted share, a figure heavily influenced by a $59.6 million non-cash gain on debt extinguishment tied to the July 2026 financing transaction and a $35.4 million non-cash goodwill impairment charge. Excluding both items, the company reported a net loss of $14.0 million, or $0.10 per diluted share, compared with a net loss of $0.18 per diluted share in the prior-year quarter. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to $2.5 million from a negative $4.1 million a year earlier.
Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Accuray, it offers a structured way to surface opportunities that match specific criteria.
Investor sentiment around Accuray has remained cautious, with shares under significant pressure over the past year as product revenue and order trends deteriorated. While the reported headline EPS of $0.07 exceeded the consensus estimate of a $0.07 loss, that beat was driven by non-cash, one-time items rather than core operating performance. The revenue miss and the sharp decline in gross product orders are likely to weigh more heavily on how the market interprets the quarter. The 0.7 book-to-bill ratio and a backlog roughly 31% lower than a year ago signal weaker near-term demand visibility, reinforcing the cautious tone that has defined the stock's recent trading.
Looking ahead, investors should focus first on whether product orders and revenue can stabilize. Gross product orders were cut roughly in half year over year, and the book-to-bill ratio of 0.7 indicates the company is consuming backlog faster than it is replenishing it. A sustained recovery in orders, particularly outside China, will be central to restoring revenue growth.
Second, watch the trajectory of the services business. With an installed base now exceeding 1,100 systems and more than $230 million in recurring annual revenue, service growth and margin expansion provide a more durable foundation. Management reported a 410-basis-point improvement in service gross margin during the quarter, and continued progress here could support profitability even as product revenue lags.
Third, monitor geopolitical and tariff developments, especially in China and the Middle East, which have constrained demand and contributed to management's decision not to provide formal fiscal 2027 guidance. Finally, keep an eye on the balance sheet. The completed TCW financing steps, including the $15 million cash investment and the exchange of $40 million of term loan debt for convertible preferred equity, are intended to reduce leverage and improve liquidity, giving the company greater flexibility to execute its turnaround.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a manufacturer of medical equipment
Industry MedicalNursingServices